393 related articles for article (PubMed ID: 16791802)
41. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma.
Fu L; Li H; Wang H; Xu B; Fan Y; Tian J
PLoS One; 2012; 7(12):e50914. PubMed ID: 23226547
[TBL] [Abstract][Full Text] [Related]
42. Differentiation of low-grade gastric MALT lymphoma and high-grade gastric MALT lymphoma: the clinical value of Ga-67 citrate scintigraphy--a pilot study.
Hsu CH; Sun SS; Kao CH; Lin CC; Lee CC
Cancer Invest; 2002; 20(7-8):939-43. PubMed ID: 12449725
[TBL] [Abstract][Full Text] [Related]
43. F-18 FDG PET/CT findings in a patient with bilateral orbital and gastric mucosa-associated lymphoid tissue lymphomas.
Suga K; Yasuhiko K; Hiyama A; Takeda K; Matsunaga N
Clin Nucl Med; 2009 Sep; 34(9):589-93. PubMed ID: 19692819
[TBL] [Abstract][Full Text] [Related]
44. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
46. [Value of endosonography in diagnostic staging of primary gastric lymphoma (MALT type)].
Hoepffner N; Lahme T; Gilly J; Menzel J; Koch P; Foerster EC
Med Klin (Munich); 2003 Jun; 98(6):313-7. PubMed ID: 12811415
[TBL] [Abstract][Full Text] [Related]
47. Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: A case series.
Albano D; Bosio G; Orlando E; Bertagna F
Hematol Oncol; 2017 Dec; 35(4):884-889. PubMed ID: 28004400
[TBL] [Abstract][Full Text] [Related]
48. FDG-PET in a patient with gastric MALT lymphoma.
Liu JD; Tai CJ; Chang CC; Lin YH; Hsu CH
Acta Oncol; 2006; 45(6):750-2. PubMed ID: 16938819
[No Abstract] [Full Text] [Related]
49. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.
Ren Y; Huang L; Han Y; Cui Z; Li J; Dong C; Liu J
Medicine (Baltimore); 2019 Feb; 98(5):e14270. PubMed ID: 30702589
[TBL] [Abstract][Full Text] [Related]
51.
Albano D; Durmo R; Treglia G; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):137-146. PubMed ID: 32029397
[TBL] [Abstract][Full Text] [Related]
52. F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma.
Minamimoto R; Tateishi U; Tomita N; Inayama Y; Omura-Minamisawa M; Tayama Y; Hata M; Kubota Y; Inoue T
Ann Nucl Med; 2010 Feb; 24(2):115-9. PubMed ID: 20077163
[TBL] [Abstract][Full Text] [Related]
53. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; de la Cruz Vicente F; Borrego-Dorado I; Ruiz Mercado M; Acevedo Báñez I; Solé Rodríguez M; Fernández López R; Pérez Vega H; Calderón-Cabrera C; Espigado Tocino I; Pérez-Simón JA; Vázquez-Albertino R
Hematol Oncol; 2015 Dec; 33(4):151-8. PubMed ID: 25407794
[TBL] [Abstract][Full Text] [Related]
54. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
55. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
56. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
57. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up.
Raderer M; Wöhrer S; Kiesewetter B; Dolak W; Lagler H; Wotherspoon A; Muellauer L; Chott A
Ann Hematol; 2015 Jun; 94(6):969-73. PubMed ID: 25579756
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma.
Ahmadzadehfar H; Rodrigues M; Zakavi R; Knoll P; Mirzaei S
Med Oncol; 2011 Dec; 28(4):1570-6. PubMed ID: 20524086
[TBL] [Abstract][Full Text] [Related]
60. [Prognostic impact of Helicobacter pylori infection and eradication therapy in gastric mucosa-associated lymphoid tissue lymphoma].
Park SH; Chi HS; Park SJ; Jang S; Park CJ; Huh JR
Korean J Lab Med; 2010 Dec; 30(6):547-53. PubMed ID: 21157137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
